GlassScriptPhysician profile
Rajnikant Kothari
NPI 1710942982
$12,490.39
in general payments reported to CMS, 2019-2025
32 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $2,771 · 2021: $935 · 2022: $1,142 · 2023: $1,415 · 2024: $1,778 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,418 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,417.97 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,256.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $1,917.94 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $1,541.79 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $1,373.09 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $903.26 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $835.34 | 2019-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $592.63 | 2019-2025 | Rexulti, Brintellix |
| Abbvie INC. | $566.07 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.65 | 2020-2025 | Caplyta |
| Allergan, INC. | $332.11 | 2019-2020 | |
| Axsome Therapeutics, INC. | $308.75 | 2022-2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $269.57 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $256.35 | 2019-2024 | Spravato |
| Neurocrine Biosciences, INC. | $216.96 | 2019-2024 | Ingrezza |
| Almatica Pharma LLC | $157.06 | 2022-2025 | Loreev Xr, Venlafaxine, Citalopram |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $113.86 | 2019-2022 | |
| Shire North American Group INC | $86.48 | 2019 | |
| Adlon Therapeutics L.P. | $81.51 | 2019-2020 | |
| Neos Therapeutics, LP | $64.03 | 2019-2021 | |
| Eisai INC. | $52.53 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $45.27 | 2019 | |
| Merck Sharp & Dohme LLC | $19.47 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2024 | |
| Noven Therapeutics, LLC | $16.18 | 2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $15.18 | 2024 | Quviviq |
| Circassia INC. | $13.86 | 2019 | |
| Novo Nordisk INC | $13.71 | 2025 | Wegovy |
| Validus Pharmaceuticals LLC | $12.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.33 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.72 | 2020 | |
| Corium, LLC | $7.68 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajnikant Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.